This document lists several drugs from different companies and the HEOR value proposition studies, HTA submissions, patient reported outcomes research, and regulatory work that has been conducted for each. Studies include US HCUP/Premier data, published studies in Australia and Canada, global health state utility valuations, EORTC trials, FDA/EMA submissions, and indirect economic analyses for conditions like CNS disorders, cardiovascular disease, endocrinology, oncology, rheumatology, and respiratory disease.